Atlas Trials

TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma

Clinical trial NCT05247996 · UNKNOWN

Trial details

NCT number
NCT05247996
Sponsor
The Central Hospital of Lishui City
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Intrahepatic Cholangiocarcinoma
Start date
2022-03-01
Primary completion
2022-12-31
Enrollment
98

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.